Statistics

Total Visits

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy4

Select a period of time:

Number of views in the range

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy4

Views

Views
December 20230
January 20241
February 20240
March 20240
April 20240
May 20243
June 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States4
 

Top cities views

Views
Boardman1
Chicago1